We are live on
!
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter
Est. Return
-11.22%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$960M
AUM Growth
-$305M
(-24%)
Cap. Flow
-$75.3M
Cap. Flow
% of AUM
-7.85%
Top 10 Holdings %
Top 10 Hldgs %
64.7%
Holding
35
New
2
Increased
6
Reduced
4
Closed
3
Avg Time Held
1
year
Top 10 Avg Time Held
0.2
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$70.9M |
| 2 |
Disc Medicine
IRON
|
+$16.5M |
| 3 |
EyePoint Inc
EYPT
|
+$12.9M |
| 4 |
Savara
SVRA
|
+$10.5M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$8.06M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inhibrx, Inc. Common Stock
INBX
|
+$61.2M |
| 2 |
Geron
GERN
|
+$57.4M |
| 3 |
Structure Therapeutics
GPCR
|
+$37.1M |
| 4 |
Astria Therapeutics
ATXS
|
+$24.6M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$13.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
C4 Therapeutics
CCCC
$342M
| $5.9M | 0.61% |
1,276,574
| – | – |
2023 Q1
5 quarters
|
|
27
Nektar Therapeutics
NKTR
$1.29B
| $4.96M | 0.52% |
266,667
| – | – |
2024 Q1
1 quarter
|
|
28
Jade Biosciences
JBIO
$875M
| $3.72M | 0.39% |
64,023
+1,129
| +2% | +$749K |
2021 Q4
10 quarters
|
|
29
AN2 Therapeutics
ANTX
$136M
| $3.34M | 0.35% |
1,555,118
| – | – |
2023 Q2
4 quarters
|
|
30
Kodiak Sciences
KOD
$5.54B
| $2.11M | 0.22% |
899,999
| – | – |
2023 Q4
2 quarters
|
|
31
DELISTED
Ventyx Biosciences
VTYX
| $730K | 0.08% |
316,195
-499,529
| -61% | -$2.08M |
2022 Q4
6 quarters
|
|
32
Cabaletta Bio
CABA
$263M
| $649K | 0.07% |
86,795
| – | – |
2022 Q4
6 quarters
|
|
|
33
Geron
GERN
$790M
| – | – |
-17,391,639
| Closed | -$57.4M | – |
|
|
34
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-1,163,356
| Closed | -$13.8M | – |
|
|
35
DELISTED
Inhibrx, Inc. Common Stock
INBX
| – | – |
-1,750,387
| Closed | -$61.2M | – |
|
Similar funds
CCMIC
TCG Crossover Management's Q2 2024 Portfolio in Review
As of Q2 2024, TCG Crossover Management held 35 positions worth $960M, down 24% from $1.26B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
TCG Crossover Management withdrew a net $75.3M in Q2 2024, closing 3 positions and reducing 4 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $61.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, TCG Crossover Management opened a new position in Disc Medicine worth $21.9M.
- TCG Crossover Management's largest Q2 2024 buy was Disc Medicine: 486,957 shares worth $21.9M.
- TCG Crossover Management added most to Abivax in Q2 2024, an estimated $70.9M increase.
- TCG Crossover Management's biggest Q2 2024 reduction was Structure Therapeutics, cutting an estimated $37.1M.
- TCG Crossover Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $61.2M.
- TCG Crossover Management's ten largest holdings make up 65% of its $960M portfolio in Q2 2024.
- TCG Crossover Management opened 2 new positions and closed 3 in Q2 2024.
- TCG Crossover Management's portfolio value fell 24% quarter-over-quarter to $960M.
Based on TCG Crossover Management's 13F filing for Q2 2024, filed 14 Aug 2024.